Tandem Diabetes Care Inc(TNDM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.93 | Insider Own | 1.24% | Shs Outstand | 69.5M | Perf Week | 16.34% |
| Market Cap | 1.34B | Forward P/E | 150.13 | EPS next Y | 119.06% | Insider Trans | - | Shs Float | 68.7M | Perf Month | 17.05% |
| Enterprise Value | 1.62B | PEG | - | EPS next Q | -0.25 | Inst Own | 114.11% | Short Float | 21.95% | Perf Quarter | 3.39% |
| Income | -0.06B | P/S | 1.28 | EPS this Y | 53.99% | Inst Trans | -1.05% | Short Ratio | 7.19 | Perf Half Y | 3.17% |
| Sales | 1.04B | P/B | 10.25 | EPS next 5Y | - | ROA | -6.24% | Short Interest | 15.09M | Perf YTD | -12.56% |
| Book/sh | 1.88 | P/C | 2.93 | EPS past 3/5Y | -27.3% -40.1% | ROE | -48.03% | 52W High | -35.18% ($29.65) | Perf Year | 28.65% |
| Cash/sh | 6.55 | P/FCF | - | Sales past 3/5Y | 8.22% 15.27% | ROIC | -7.45% | 52W Low | 56.77% ($12.26) | Perf 3Y | 6.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 70.03% | Gross Margin | 55.99% | Volatility(W/M) | 6.24% 5.49% | Perf 5Y | -85.23% |
| Dividend TTM | - | EV/Sales | 1.56 | Sales Y/Y TTM | 3.92% | Oper. Margin | -4.17% | ATR (14) | 0.98 | Perf 10Y | -67.97% |
| Dividend Ex-Date | - | Quick Ratio | 2.65 | EPS Q/Q | 60.75% | Profit Margin | -6.08% | RSI (14) | 67 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.18 | Sales Q/Q | 5.59% | SMA20 | 15.28% ($16.67) | Beta | 1.62 | Target Price | $28.15 |
| Payout | - | Debt/Eq | 5.67 | Earnings | 2026/11/5 | SMA50 | 5.34% ($18.25) | Rel Volume | 0.98 | Prev Close | $18.9 |
| Employees | 2500 | LT Debt/Eq | 5.51 | EPS/Sales Surpr. | 4.37% -0.17% | SMA200 | 1.4% ($18.95) | Avg Volume(3M) | 2.10M | Price | $19.22 |
| IPO | 2013/11/14 | Option/Short | Yes/Yes | Trades | 14705 | Volume | 2,059,437 | Change | 1.69% |
💉 Tandem Diabetes Care (TNDM) is a US medical device company that develops insulin pumps and automated insulin delivery systems for diabetes patients. The company has established a strong presence in the type 1 and type 2 diabetes management market with its flagship t:slim insulin pump and the compact Tandem Mobi pump, with its automated algorithms that integrate with continuous glucose monitors serving as its core competitive advantage.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded about as much as usual. That is 98% of its average volume.
Next earnings report: November 5
8 days to go.
TNDM has weak earnings and a weak balance sheet
Of every $100 in sales, $4.17 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +54.0% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $128. Peers typically go for $336.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -85.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #35 of 142 in the industry
Based on market cap of $1B.
CNMD#34 Conmed Corp $1B PER 25.5 TNDM#35 Tandem Diabetes Care Inc $1B PER - 
ENOV#36 Enovis Corp $1B PER - 
BVS#37 Bioventus Inc $1B PER 18.6 
BBNX#38 Beta Bionics Inc $1B PER - 
FAQ
What kind of company is TNDM?
TNDM belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TNDM?
The market cap of TNDM is approximately $1.3B, ranking 2,367 within its sector.
What is the 52-week high and low for TNDM?
TNDM has recorded a 52-week high of $29.65 and a low of $12.26.
